{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:07:43Z","timestamp":1793963263724,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of the Epstein-Barr virus (EBV) status in the blood for predicting survival in post-transplantation lymphoproliferative disorders\u2013diffuse large B-cell lymphoma (PTLD\u2013DLBCL) is unknown. We evaluated the prognostic values of pre-treatment EBV-encoded small RNA (EBER) detected with in situ hybridization in tissues and EBV DNA in the whole blood (WB) and plasma in 58 patients with monomorphic PTLD\u2013DLBCL after solid organ transplantation. There were no significant differences in the rates of overall response, complete response, and survival according to EBER EBV and WB EBV status. In contrast, patients with positive plasma EBV DNA had significantly lower rates of overall response (60.0% vs. 94.4%, <jats:italic>P<\/jats:italic>\u2009=\u20090.043) and complete response (40.0% vs. 88.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.019) as well as worse progression-free survival (PFS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.035) and overall survival (OS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.039) compared with patients with negative plasma EBV DNA. In multivariate analysis, plasma EBV DNA positivity was a significantly unfavorable prognostic factor for PFS [hazard ratio (HR) 4.92, 95% confidence interval (CI) 1.22\u201319.86, <jats:italic>P<\/jats:italic>\u2009=\u20090.025] and OS (HR 4.48, 95% CI 1.14\u201317.63, <jats:italic>P<\/jats:italic>\u2009=\u20090.032). Despite small number of 6 patients with plasma EBV positivity, plasma EBV DNA positivity might be more prognostic for survival than EBER or WB EBV DNA positivity in patients with monomorphic PTLD\u2013DLBCL.<\/jats:p>","DOI":"10.1038\/s41598-021-82534-4","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:10:36Z","timestamp":1612350636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders\u2013diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Jwa Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heungsup","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah Ra","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Sik","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"82534_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","volume":"127","author":"M Cazzola","year":"2016","unstructured":"Cazzola, M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood 127, 2361\u20132364 (2016).","journal-title":"Blood"},{"key":"82534_CR2","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019\u20135032 (2011).","journal-title":"Blood"},{"key":"82534_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","volume":"4","author":"G Opelz","year":"2004","unstructured":"Opelz, G. & Dohler, B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4, 222\u2013230 (2004).","journal-title":"Am. J. Transplant."},{"key":"82534_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1600-6143.2006.01294.x","volume":"6","author":"WK Kremers","year":"2006","unstructured":"Kremers, W. K. et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am. J. Transplant. 6, 1017\u20131024 (2006).","journal-title":"Am. J. Transplant."},{"key":"82534_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1399-0012.2010.01392.x","volume":"26","author":"SO Yoon","year":"2012","unstructured":"Yoon, S. O. et al. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990\u20132009. Clin. Transplant. 26, 67\u201373 (2012).","journal-title":"Clin. Transplant."},{"key":"82534_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe, R. et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 13, 196\u2013206 (2012).","journal-title":"Lancet Oncol."},{"key":"82534_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1080\/10428190802239162","volume":"49","author":"AB Oton","year":"2008","unstructured":"Oton, A. B. et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk. Lymphoma 49, 1738\u20131744 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"82534_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMra032015","volume":"350","author":"DA Thorley-Lawson","year":"2004","unstructured":"Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328\u20131337 (2004).","journal-title":"N. Engl. J. Med."},{"key":"82534_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM200008173430707","volume":"343","author":"JI Cohen","year":"2000","unstructured":"Cohen, J. I. Epstein-Barr virus infection. N. Engl. J. Med. 343, 481\u2013492 (2000).","journal-title":"N. Engl. J. Med."},{"key":"82534_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/rmv.1816","volume":"25","author":"CJ Houldcroft","year":"2015","unstructured":"Houldcroft, C. J. & Kellam, P. Host genetics of Epstein-Barr virus infection, latency and disease. Rev. Med. Virol. 25, 71\u201384 (2015).","journal-title":"Rev. Med. Virol."},{"key":"82534_CR11","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","volume":"15","author":"MR Luskin","year":"2015","unstructured":"Luskin, M. R. et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am. J. Transplant. 15, 2665\u20132673 (2015).","journal-title":"Am. J. Transplant."},{"key":"82534_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","volume":"19","author":"V Leblond","year":"2001","unstructured":"Leblond, V. et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J. Clin. Oncol. 19, 772\u2013778 (2001).","journal-title":"J. Clin. Oncol."},{"key":"82534_CR13","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","volume":"25","author":"B Maecker","year":"2007","unstructured":"Maecker, B. et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J. Clin. Oncol. 25, 4902\u20134908 (2007).","journal-title":"J. Clin. Oncol."},{"key":"82534_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3109\/0284186X.2013.844853","volume":"53","author":"A Kinch","year":"2014","unstructured":"Kinch, A. et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 53, 669\u2013679 (2014).","journal-title":"Acta Oncol."},{"key":"82534_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bjh.13621","volume":"171","author":"F Montanari","year":"2015","unstructured":"Montanari, F. et al. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. Br. J. Haematol. 171, 491\u2013500 (2015).","journal-title":"Br. J. Haematol."},{"key":"82534_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-017-0087-0","volume":"6","author":"R Bishnoi","year":"2017","unstructured":"Bishnoi, R. et al. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp. Hematol. Oncol. 6, 26. https:\/\/doi.org\/10.1186\/s40164-017-0087-0 (2017).","journal-title":"Exp. Hematol. Oncol."},{"key":"82534_CR17","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2015-09-672030","volume":"127","author":"JA Kanakry","year":"2016","unstructured":"Kanakry, J. A. et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood 127, 2007\u20132017 (2016).","journal-title":"Blood"},{"key":"82534_CR18","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1080\/10428194.2017.1300894","volume":"58","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma. Leuk. Lymphoma 58, 2349\u20132355 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"82534_CR19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/ijc.30566","volume":"140","author":"BM Haverkos","year":"2017","unstructured":"Haverkos, B. M. et al. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int. J. Cancer 140, 1899\u20131906 (2017).","journal-title":"Int. J. Cancer"},{"key":"82534_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim, S. J. et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 17, 389\u2013400 (2016).","journal-title":"Lancet Oncol."},{"key":"82534_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00277-016-2610-5","volume":"95","author":"JH Park","year":"2016","unstructured":"Park, J. H. et al. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Ann. Hematol. 95, 801\u2013808 (2016).","journal-title":"Ann. Hematol."},{"key":"82534_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/1078-0432.CCR-05-2008","volume":"12","author":"MK Gandhi","year":"2006","unstructured":"Gandhi, M. K. et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin\u2019s lymphoma. Clin. Cancer Res. 12, 460\u2013464 (2006).","journal-title":"Clin. Cancer Res."},{"key":"82534_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","journal-title":"N. Engl. J. Med."},{"key":"82534_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"82534_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fonc.2019.00062","volume":"9","author":"H Kimura","year":"2019","unstructured":"Kimura, H. & Kwong, Y. L. EBV viral loads in diagnosis, monitoring, and response assessment. Front. Oncol. 9, 62. https:\/\/doi.org\/10.3389\/fonc.2019.00062 (2019).","journal-title":"Front. Oncol."},{"key":"82534_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","volume":"1045","author":"H Kimura","year":"2018","unstructured":"Kimura, H. EBV in T-\/NK-cell tumorigenesis. Adv. Exp. Med. Biol. 1045, 459\u2013475 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"82534_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/rmv.582","volume":"18","author":"H Kimura","year":"2008","unstructured":"Kimura, H., Ito, Y., Suzuki, R. & Nishiyama, Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev. Med. Virol. 18, 305\u2013319 (2008).","journal-title":"Rev. Med. Virol."},{"key":"82534_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1600-6143.2008.02183.x","volume":"8","author":"DE Tsai","year":"2008","unstructured":"Tsai, D. E. et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am. J. Transplant. 8, 1016\u20131024 (2008).","journal-title":"Am. J. Transplant."},{"key":"82534_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/00007890-200209150-00012","volume":"74","author":"HJ Wagner","year":"2002","unstructured":"Wagner, H. J. et al. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 74, 656\u2013664 (2002).","journal-title":"Transplantation"},{"key":"82534_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/cid\/ciy542","volume":"68","author":"J Muncunill","year":"2019","unstructured":"Muncunill, J. et al. Plasma Epstein-Barr virus load as an early biomarker and prognostic factor of human immunodeficiency virus-related lymphomas. Clin. Infect. Dis. 68, 834\u2013843 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"82534_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","volume":"10","author":"E Tse","year":"2017","unstructured":"Tse, E. & Kwong, Y. L. The diagnosis and management of NK\/T-cell lymphomas. J. Hematol. Oncol. 10, 85. https:\/\/doi.org\/10.1186\/s13045-017-0452-9 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"82534_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/CBM-160336","volume":"19","author":"J Ding","year":"2017","unstructured":"Ding, J., Karp, J. E. & Emadi, A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 19, 353\u2013363 (2017).","journal-title":"Cancer Biomark."},{"key":"82534_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","volume":"54","author":"AM Ferraris","year":"1979","unstructured":"Ferraris, A. M., Giuntini, P. & Gaetani, G. F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54, 928\u2013932 (1979).","journal-title":"Blood"},{"key":"82534_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bjc.1993.509","volume":"68","author":"R Garcia","year":"1993","unstructured":"Garcia, R. et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin\u2019s disease. Br. J. Cancer 68, 1227\u20131231 (1993).","journal-title":"Br. J. Cancer"},{"key":"82534_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/path.1711750303","volume":"175","author":"M Hummel","year":"1995","unstructured":"Hummel, M., Anagnostopoulos, I., Korbjuhn, P. & Stein, H. Epstein-Barr virus in B-cell non-Hodgkin\u2019s lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J. Pathol. 175, 263\u2013271 (1995).","journal-title":"J. Pathol."},{"key":"82534_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/PAI.0000000000000562","volume":"27","author":"IJ Miller","year":"2019","unstructured":"Miller, I. J. Epstein Barr Virus infection can be a secondary event in B-cell lymphomas: a review of 338 cases and a novel finding of zonal EBER+ tumor cells showing features of progression from underlying EBV-negative lymphoma. Appl. Immunohistochem. Mol. Morphol. 27, 165\u2013173 (2019).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"82534_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","volume":"6","author":"RL Elstrom","year":"2006","unstructured":"Elstrom, R. L. et al. Treatment of PTLD with rituximab or chemotherapy. Am. J. Transplant. 6, 569\u2013576 (2006).","journal-title":"Am. J. Transplant."},{"key":"82534_CR38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.20795","volume":"82","author":"FK Buadi","year":"2007","unstructured":"Buadi, F. K. et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am. J. Hematol. 82, 208\u2013214 (2007).","journal-title":"Am. J. Hematol."},{"key":"82534_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3324\/haematol.10595","volume":"92","author":"S Choquet","year":"2007","unstructured":"Choquet, S. et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92, 273\u2013274 (2007).","journal-title":"Haematologica"},{"key":"82534_CR40","first-page":"3945S","volume":"9","author":"M Orjuela","year":"2003","unstructured":"Orjuela, M. et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin. Cancer Res. 9, 3945S-3952S (2003).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82534-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:09:33Z","timestamp":1670036973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82534-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82534"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82534-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2880"}}